220
Participants
Start Date
May 31, 2013
Primary Completion Date
February 29, 2016
Study Completion Date
February 29, 2016
TRx0237
TRx0237 100 mg tablet will be administered twice daily.
Placebo
Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Alzheimer Research Center Amsterdam, Amsterdam
Neuroscience Research Australia, Randwick
Erasmus University Medical Center, Rotterdam
Box Hill Hospital, Box Hill
Jeroen Bosch Ziekenhuis, afdeling geriatrie, 's-Hertogenbosch
Neurodegenerative Disorders Research Pty Ltd, West Perth
University Hospital Centre Zagreb, Zagreb
University Psychiatric Hospital Vrapče, Zagreb
Charité-Universitätsmedizin Berlin Klinik für Psychiatrie und Psychotherapie, Berlin
Neurology I, Department of Neuroscience, University of Torino, Torino
Integrative Clinical Trials LLC, Brooklyn
Neurological Associates of Albany, P. C., Albany
Memory Clinic, ECRC, Berlin
The Clinical Trial Center, LLC, Jenkintown
Hospital of the University of Pennsylvania, Department of Neurology, Philadelphia
"Fondazione IRCCS Istituto Neurologico Carlo Besta", Milan
Universitätsklinikum Hamburg-Eppendorf Klinik für Psychiatrie und Psychotherapie, Hamburg
Johns Hopkins University, Baltimore
University of Virginia, Charlottesville
Unità di Neuroimmagine e Epidemiologia Alzheimer, Brescia
UNC Department of Neurology, Physicians Office Building, Chapel Hill
Department of Neurology, Emory University, Atlanta
Mayo Clinic, Jacksonville
Compass Research, LLC, Orlando
University of South Florida, Tampa
Meridien Research, Brooksville
University Hospitals Case Medical Center, Neurology Clinical Trials Unit, Cleveland
Indiana University Department of Neurology, Indianapolis
Hospital Viamed Montecanal, Neurology Department, Zaragoza
Ceuta University Hospital; Neurology, Ceuta
Mayo Clinic, Department of Neurology, Rochester
Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village
Fondazione Universita' Gabriele D'Annunzio di Chieti, Chieti Scalo
Rivers Wellness and Research Institute, Oklahoma City
Klinik und Poliklinik für Psychiatrie und Psychotherapie der Technischen Universität München, München
PRA Health Sciences, Phase 2/3 Outpatient and CNS Clinic, Salt Lake City
Universitäts - und Rehabilitationskliniken Ulm, Neurologie, Ulm
David Geffen School of Medicine at UCLA, UCLA Neurological Services, Los Angeles
The Shankle Clinic, Newport Beach
Memory and Aging Centre, San Francisco
National Neuroscience Institute Department of Neurology, Singapore
Neurological Clinical Research Institute (NCRI) Massachusetts General Hospital, Boston
Memory Enhancement Center of America, Inc., Eatontown
The Memory Clinic, Bennington
Heritage Medical Research Clinic-University of Calgary, Calgary
University of British Columbia Hospital, Clinic for Alzheimer Disease and Related Disorders, Vancouver
Vancouver Island Health Authority, Victoria
True North Clinical Research, Halifax
Geriatric Clinical Trials Group, Parkwood Institute, London
Toronto Memory Program, Toronto
University Health Network, Toronto Western Hospital, Memory Clinic, Toronto
McGill Centre for Studies in Aging, Alzheimer Disease Research Unit, Verdun
NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska, Poznan
Euromedis Sp. z o.o., Szczecin
Psychomedical Consult, Bucharest
Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona
NHS Grampian, OAP Directorate, Aberdeen
The Barberry Out-Patients Department, Birmingham
2gether NHS foundation trust, Cheltenham
Kingsway Hospital, Derby
St Margaret's Hospital Mental Health Unit, Epping
Cognition Health Ltd., London
Imperial College Healthcare NHS Trust - Charing Cross Hospital, London
Dementia Research Center at Queens Square, London
Nuffield Department of Clinical Neurosciences, Oxford
Redwoods Centre, Shrewsbury
Wessex Neurological Centre, Southampton General Hospital, Southampton
TauRx Therapeutics Ltd
INDUSTRY